Accel Wealth Management’s Galectin Therapeutics GALT Stock Holding History

Accel Wealth Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-334	Closed	-$1K	–	1071
2022 Q2	$1K	Hold	334	–	–	﹤0.01%	952
2022 Q1	$1K	Hold	334	–	–	﹤0.01%	902
2021 Q4	$1K	Hold	334	–	–	﹤0.01%	903
2021 Q3	$1K	Hold	334	–	–	﹤0.01%	804
2021 Q2	$1K	Hold	334	–	–	﹤0.01%	881
2021 Q1	$1K	Hold	334	–	–	﹤0.01%	847
2020 Q4	$1K	Buy	+334	New	+$876	﹤0.01%	808

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Accel Wealth Management's GALT Position: Q3 2022 in Review

Accel Wealth Management sold out of Galectin Therapeutics (GALT) in Q3 2022, closing a stake of 334 shares — an estimated $1K sold.

Accel Wealth Management first reported a position in GALT in Q4 2020 and held it in 7 quarters. The position peaked at $1K in Q2 2022. 59 funds tracked by Wall St. Rank hold GALT as of Q3 2022.

Accel Wealth Management reported no remaining Galectin Therapeutics position as of Q3 2022 after selling out during the quarter.
Accel Wealth Management sold 334 Galectin Therapeutics shares in Q3 2022, an estimated $1K.
Accel Wealth Management first reported a position in Galectin Therapeutics in Q4 2020 and held it in 7 quarters.
Accel Wealth Management's Galectin Therapeutics position peaked at $1K in Q2 2022.
59 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2022.

Based on Accel Wealth Management's 13F filing for Q3 2022, filed 12 Oct 2022.